A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)

PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
of Oral MDV3100 in Chemotherapy-Naïve Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Category & Conditions:
Cancer
Medicine:
Xtandi (enzalutamide)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
C3431003
Open Plain Language Summary Result:Click here